Professor of Medicine, University Tex Houston
Oncology
Dr. James L. Abbruzzese, MD
|
|
Give Review
James Abbruzzese works in the field of Oncology. He studied medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10/19 in Research/PrimaryCare. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Fellow (FASCO)" and "Super Doctor". Dr. James L. Abbruzzese is also a published doctor. He has 99 publication published. The most recent publication is: RECQ1 A159C Polymorphism Is Associated WithOverall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRGOncology Radiation Therapy Oncolog... He is registered with Medicare.
Publications
- RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncolog...
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
- Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCarcinoma: NEOADJUVANT THERAPIES AND PATHOLOGY.
- New Option for the Initial Management of Metastatic Pancreatic Cancer?
- Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenoCarcinoma.
- Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in HepatoCellular Carcinoma.
- SOX9: a useful marker for pancreatic Ductal lineage of pancreatic neoplasms.
- Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival Analyses of 64 cases from a single institution.
- Evaluating physician performance in oncology: moneyball becomes impactball.
- The CUL7/F-box and WD Repeat Domain Containing 8 (CUL7/Fbxw8) Ubiquitin Ligase Promotes Degradation of Hematopoietic Progenitor Kinase 1.
- Clinicopathologic features and prognosis of duodenal adenoCarcinoma and comparison with ampullary and pancreatic ductal adenoCarcinoma.
- Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic Ductal adenoca...
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival.
- Genetic variation in the PNPLA3 gene and hepatoCellular carcinoma in USA: Risk and prognosis prediction.
- Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification.
- Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar HepatoCellular Carcinoma.
- Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate,...
- The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic Cancer.
- The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head AdenoCarcinoma.
- Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells.
- Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis.
- BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.
- Association of diabetes and perineural invasion in pancreatic Cancer.
- Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenoCarcinoma.
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
- Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour Cells.
- Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal AdenoCarcinoma.
- Multimodality Therapy Offers a Chance for Cure in Patients with Pancreatic AdenoCarcinoma Deemed Unresectable at First Operative Exploration.
- Response of borderline resectable pancreatic Cancer to neoadjuvant therapy is not reflected by radiographic indicators.
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer.
- A Population-Based Comparison of AdenoCarcinoma of the Large and Small Intestine: Insights Into a Rare Disease.
- Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenoCarcinoma treated with neoadjuva...
- Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenoCarcinoma is associated with a better prognosis.
- Histologic grading the extent of residual Carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenoCarcinoma: A predictor for patient outcome.
- Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatoCellular carcinoma.
- Mast Cells in Tumor Microenvironment Promotes the in vivo Growth of Pancreatic Ductal Adenocarcinoma.
- The use of GTX as second-line and later chemotherapy for metastatic pancreatic Cancer: a retrospective analysis.
- Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic Cancer.
- I-CLIP: Improved Stratification of Advanced HepatoCellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score.
- Introducing CCR Perspectives in Drug Approval.
- Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1.
- Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete Proinflammatory Factors that Contribute to Malignant Progression by Inducing an EMT cell phenotype.
- Post-therapy pathologic stage and survival in patients with pancreatic ductal adenoCarcinoma treated with neoadjuvant chemoradiation.
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic AdenoCarcinoma: Correlation of...
- DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic Cancer.
- V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatoCellular carcinoma for clinical trials.
- Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer.
- Glucose metabolism gene variants modulate the risk of pancreatic Cancer.
- Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic Cancer.
- Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary.
- Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic Cancer: a phase II trial.
- Overexpression of receptor tyrosine kinase Axl promotes tumor Cell invasion and survival in pancreatic ductal adenocarcinoma.
- Association of multi-drug resistance gene polymorphisms with pancreatic Cancer outcome.
- Glucose metabolism gene polymorphisms and clinical outcome in pancreatic Cancer.
- ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma.
- Therapeutic applications of NSAIDS in Cancer: special emphasis on tolfenamic acid.
- DNA mismatch repair gene polymorphisms affect survival in pancreatic Cancer.
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic Cancer.
- Chemoprevention of pancreatic Cancer: ready for the clinic?
- Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
- New strategies in pancreatic Cancer: emerging epidemiologic and therapeutic concepts.
- Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic Cancer.
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenoCarcinoma: Southwest Oncology Group-directed intergro...
- High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenoCarcinoma.
- Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic Cancer treated with neoadjuvant chemoradiation.
- Association of diabetes duration and diabetes treatment with the risk of hepatoCellular carcinoma.
- S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenoCarcinoma of the stomach.
- Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal Cancer.
- Introducing new strategies in...
- A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic Cancer.
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with...
- Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic Cancer survival and drug toxicity.
- Barriers to Integrating Gene Profiling for Stage II Colon Cancer.
- Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing Acute neurotoxicity.
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal Cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
- Antidiabetic therapies affect risk of pancreatic Cancer.
- Epithelial to mesenchymal transition contributes to drug resistance in pancreatic Cancer.
- Body mass index and risk, age of onset, and survival in patients with pancreatic Cancer.
- Phase II study of capecitabine and oxaliplatin for advanced adenoCarcinoma of the small bowel and ampulla of Vater.
- Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma Cells is mediated by oxidative stress.
- Activator protein-1 has an essential role in pancreatic Cancer cells and is regulated by a novel Akt-mediated mechanism.
- Association between hypothyroidism and hepatoCellular carcinoma: a case-control study in the United States.
- Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.
- Hidden biases in an observational study of bevacizumab beyond progression.
- Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic Cancer.
- Long-term survival after multidisciplinary management of resected pancreatic adenoCarcinoma.
- Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic Cancer cells is linked with activation of the notch signaling pathway.
- Tolfenamic acid enhances pancreatic Cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
- The association of family history of liver Cancer with hepatocellular carcinoma: a case-control study in the United States.
- Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic Cancer.
- Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic Cancer patients treated with preoperative chemoradiation.
- Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatoCellular carcinoma.
- DNA repair gene polymorphisms and risk of pancreatic Cancer.
- Highlights of the 2008 San Antonio Breast Cancer Symposium.
- Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic Cancer.
- Novel approaches to 'borderline resectable' pancreatic Tumors.
- Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenoCarcinoma.
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic Cancer.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Johns Hopkins Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Prostate Cancer Screening Exam (DRE)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FASCO)
- Super Doctor
Education
-
Johns Hopkins University -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1134233224 | |
| NPPES Provider LastName | ABBRUZZESE | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 318.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 55.0 | |
| Percent Opioid Claims | 17.3 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134233224 |
| Last Name Of The Provider | ABBRUZZESE |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Elizabeth J. Shpall, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin N. Raber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad Pecot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Celyne Bueno-Hume, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sadia Saleem, MD
This Doctor is OpenDoctor Recommended.
|